asco lung cancer highlights, pt 13: immune checkpoint inhibitor mpdl3280a in advanced nsclc
Published 10 years ago • 342 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
8:35
asco lung cancer roundtable - nsclc - the cityscape trial: anti tigit & immune checkpoint inhibitor
-
7:44
asco lung cancer highlights, part 1: introduction to stage iii nsclc
-
8:45
asco lung cancer highlights, part 2: optimizing radiation for stage iii nsclc
-
8:40
asco lung cancer highlights, part 3: immunotherapy for stage iii nsclc
-
5:20
asco lung cancer highlights, pt 11: nintedanib with second line chemotherapy
-
6:20
asco lung cancer highlights, part 4: exploring the role of trimodality therapy for stage iii nsclc
-
8:13
asco 2021 lung recap: fda analysis of immunotherapy with or without chemo in adv nsclc and low pdl-1
-
6:17
asco 2021 lung recap: immune therapy for brain metastases
-
6:10
asco 2021 lung recap: circulatory tumor dna
-
4:56
dual immune checkpoint blockade with or without chemotherapy - lung cancer onctalk 2022
-
7:39
chemotherapy and immunotherapy for patients with kras mutations - asco lung review 2022
-
5:40
asco lung cancer highlights, pt 12: ganetespib with second line chemotherapy
-
4:45
the skyscraper trial: treatments for extensive stage small cell lung cancer - asco lung review 2022
-
2:22
aegean trial: perioperative durvalumab for nsclc - onctalk lung 2023
-
5:45
asco highlights, pt 10: after resistance to crizotinib in alk-positive advanced nsclc
-
23:32
gracecast-077_lung-cancer_asco 2011 highlights - advanced/metastatic nsclc
-
8:45
can we harness our immune system to fight nsclc?
-
12:34
asco lung cancer roundtable - nsclc - the sindas trial: addition of sbrt to a systemic tki for egfr
-
7:54
keytruda combined with anti-vegf treatment:use in patients with advanced nsclc-asco lung review 2022